Alemtuzumab

Sandhoff Disease

Masonic Cancer Center, University of Minnesotamonoclonal_antibodyPhase 2Dormant

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

1 Active assets in the Sandhoff Disease cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Masonic Cancer Center, University of Minnesota	Phase 2/3	BB
BUSULFANUM Masonic Cancer Center, University of Minnesota	Phase 2/3	B
Venglustat Genzyme, a Sanofi Company	Phase 3	B
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Masonic Cancer Center, University of Minnesota	Phase 2/3	B
Hydroxyurea Masonic Cancer Center, University of Minnesota	Phase 2	B
Clofarabine Masonic Cancer Center, University of Minnesota	Phase 2	B
MELPHALAN Masonic Cancer Center, University of Minnesota	Phase 2	B
Duoc-01 Joanne Kurtzberg, MD	Phase 1	CC